ClinicalTrials.gg
RecruitingNCT06328712Updated May 26, 2026

Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)

A Phase 1/2 interventional study of EN001 and EN001 Placebo in Charcot-Marie-Tooth Disease Type 1A, sponsored by ENCell. Recruiting at 3 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by ENCell · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

A Phase 1b/2a Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients with Charcot-Marie-Tooth Disease type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)

Read the detailed description

This clinical trial consists of two stages (Phase 1b and Phase 2a). Phase 1b is designed with a 3+3 dose escalation design to evaluate the safety, including tolerability, of EN001 and explore efficacy. Phase 2a will evaluate the efficacy and safety of EN001 in comparison with placebo.

-Phase 1b The study was designed using the traditional 3+3 dose escalation method to confirm the maximum tolerated dose (MTD) and determine the recommended phase 2 dose (RP2D).

Dose increase is carried out until the maximum tolerated dose (MTD) is confirmed at the high dose (Cohort 2), which is the maximum planned dose (MPD), or at a lower dose. The maximum tolerated dose (MTD) is defined as the highest dose at which the incidence of dose limiting toxicity (DLT) is lower than 33%. To determine the maximum tolerated dose (MTD), 3-6 test subjects from each dose cohort are enrolled and EN001 is administered twice at 4-week intervals, and dose-limiting toxicity (DLT) is evaluated until 4 weeks (visit 6).

The safety review committee (SRC) is comprised of the principal investigator, sponsor, etc. as members, and EN001 confirmed by the end of each cohort (end of dose-limiting toxicity (DLT) evaluation of the last dosed subject in the cohort). Safety data are comprehensively reviewed to determine all matters related to dose, such as increase or decrease in dose, and finally the recommended phase 2 dose (RP2D) is determined.

-Phase 2a The Phase 2a is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will be randomly assigned in a 1:1:1 ratio to Study Group 1 (EN001 Low dose), Study Group 2 (EN001 High dose), or the placebo control group. The efficacy and safety of EN001 will be evaluated in comparison with placebo.

In addition, test subjects participating in phase 1b/2a will be followed up for safety and effectiveness for 5 years from the time of last EN001 administration according to the long-term follow-up protocol.

02

Conditions studied

  • Charcot-Marie-Tooth Disease Type 1A

Keywords

  • EN001
  • CMT1A
  • ENCell
  • MSC
  • CMT
03

In context

Charcot-Marie-Tooth Disease

114 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 38 are open to participants now.

This study's planned enrollment of 27 is below the median of 41 across 62 interventional studies indexed under Charcot-Marie-Tooth Disease.

Browse Charcot-Marie-Tooth Disease studies →

Lead sponsor

ENCell is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals who have voluntarily agreed to participate in this clinical trial.
  2. Men and women aged 19 years or older at the time of providing written consent.
  3. Individuals who meet all of the following genetic and clinical diagnostic criteria:

    1. Genetic diagnosis: CMT1A type
    2. Clinical diagnosis:

      • Those with a CMT Neuropathy Score version 2 (CMTNSv2) between 2 or more and 20 or less.
      • Those experiencing muscle weakness due to foot dorsiflexion impairment.
  4. Women and men of who have agreed to use the appropriate method(s) outlined in the protocol during the clinical trial period.

    • Appropriate contraception is defined as follows and is achieved by applying one or more methods of contraception.

      • Hormonal contraceptives
      • Implantation of an intrauterine device or intrauterine system
      • Sterilization procedures (vasectomy, tubal ligation, etc.)
      • Double contraceptive method: male condom along with other contraceptive methods [hormonal contraceptives (oral contraceptives, subcutaneous contraceptives (Implanon, etc.), long-acting contraceptive injections, emergency contraceptive pills), implantation of an intrauterine device or intrauterine system (Loop, Mirena), Infertility procedures (vasectomy, tubal ligation, etc.)]
      • Abstinence: Absolute abstinence. If, in the examiner's judgment, the subject's age, occupation, lifestyle, or sexual orientation warrants contraception, strict abstinence from sexual intercourse is also acceptable. However, periodic abstinence (e.g. Karenda method, ovulation method, symptomatic temperature method), abstinence, and external vaginal ejaculation are not recognized as appropriate contraceptive methods.

Exclusion criteria

Exclusion Criteria:

  1. Those with the following comorbidities confirmed at the time of screening

    1. Subjects with neuromuscular diseases other than CMT1A or neuropathy- inducing factors (uremia) that may affect the safety and efficacy evaluation of this clinical trial, according to the judgment of the investigator.
    2. Individuals diagnosed with type 1 or type 2 diabetes
    3. Individuals diagnosed with active pulmonary tuberculosis
    4. Patients with uncontrolled hypertension (systolic blood pressure over 180 mmHg or diastolic blood pressure over 110 mmHg)
    5. Subjects with other diseases, including significant heart, lung, liver, kidney, hematological, immunological or behavioral diseases or malignant tumors, according to the investigator's judgment
    6. Individuals who display the specified test abnormalities in laboratory tests at the time of screening:

      • or ALT > 3 x
      • Total > 1.5 x ULN
      • Serum creatinine > 1.5 x ULN
      • Any one of the serum virus tests (, anti-HBc, anti-, Ag/Ab) is positive (If anti-HBc positive) However, registration is possible if the HBV DNA test result is negative. (If anti-HCV positive) However, registration is possible if the HCV RNA test result is negative.
    7. Those who have ankle contracture or have undergone surgery that may affect muscle strength measurement tests
  2. Medical history and surgical history

    1. Those who have undergone orthopedic surgery (bone or ligament correction, artificial joint implantation, osteotomy, arthroscopic surgery) on the lower extremities within 24 weeks before screening
    2. Those with a history of stroke or cerebral ischemic attack within 48 weeks before screening
    3. Those with a history of coronary artery disease, such as myocardial infarction or incomplete angina, within 48 weeks before screening
    4. Those with a history of malignant tumor within 240 weeks before screening (excluding basal cell carcinoma or squamous cell carcinoma that occurs on the skin)
  3. Drugs and therapies prohibited from concurrent use

    1. Those who participated in another clinical trial and administered/applied clinical trial drugs/medical devices within 4 weeks before screening
    2. Those who administered/applied , chemotherapy, radiation therapy, etc. within 12 weeks before screening
    3. Persons who have administered cell therapy or gene therapy throughout their lives
    4. Persons who have administered neurotoxic drugs that can accelerate peripheral nerve damage ① Within 1 week of Screening

      • Anti-inflammatory agents or antibiotics: Colchicine, Nitrofurantoin
      • Antiretroviral agents: Zalcitabine, Stavudine
      • Dichloroacetate

        ② Within 55 weeks of Screening

      • Antiarrhythmic agent: Amiodarone
      • Antiparasitic agent: Suramin
  4. Persons with to the components of clinical products
  5. Those who have had metal substances (heart pacemaker, nerve stimulator, cochlear implant, etc.) implanted in their body
  6. Pregnant, lactating, or planning to become pregnant during the clinical trial period
  7. Subjects with a psychiatric disorder (anxiety disorder, claustrophobia, or other significant mental disorder) or a history of drug and alcohol abuse that may affect the clinical trial, according to the judgment of the investigator.
  8. Those who are deemed inappropriate to participate in clinical trials according to the judgment of the investigator
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (estimated)

Study arms

  • Active comparator
    Phase1b - Cohort 1

    Phase 1b - Low dose

    Drug: EN001

  • Active comparator
    Phase 1b - Cohort 2

    EN001 High dose

    Drug: EN001

  • Active comparator
    Phase 2a - Cohort 1

    EN001 Low dose

    Drug: EN001

  • Active comparator
    Phase 2a - Cohort 2

    EN001 High dose

    Drug: EN001

  • Placebo comparator
    Phase 2a - Placebo

    EN001 Placebo

    Drug: EN001 Placebo

Interventions

  • DrugEN001

    * Cohort 1: EN001 Low dose administered intravenously (IV) 2 times at 4 week intervals. * Cohort 2: EN001 High dose administered intravenously (IV) 2 times at 4 week intervals.

    Also known as: EN001(Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells(WJ-MSCs) )

  • DrugEN001 Placebo

    EN001 Placebo administered intravenously (IV) 2 times at 4 week intervals.

06

What researchers measure

Primary outcomes

  1. [Phase 1b] Dose limiting toxicity (DLT) and adverse drug reactions related to discontinuation of investigational product administration

    Present the frequency and percentage of dose-limiting toxicity (DLT) occurrence across dose cohorts, along with detailed information on the types of DLTs. Adverse events related to discontinuation of clinical investigational drug administration, discontinuation of clinical investigational drug administration Regarding related adverse drug reactions, the number of subjects in each cohort, incidence rate (%), and Two-sided 95% confidence intervals and number of occurrences are presented.

    Time frame: Up to 8 weeks

  2. [Phase 2a] Change from baseline in the CMT Neuropathy Score (CMTNSv2) at Week 24.

    For all efficacy outcome measures, descriptive statistics (number of subjects, mean, standard deviation, median, minimum, and maximum) will be presented by treatment group and assessment time point, along with two-sided 95% confidence intervals.

    Time frame: at Week 24

Secondary outcomes

  1. [Phase1b, Phase2a] CMTNSv2 score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  2. [Phase1b, Phase2a] CMT examination score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  3. [Phase1b, Phase2a] Rasch-modified CMTNSv2 score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  4. [Phase1b, Phase2a] Rasch-modified CMTES score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  5. [Phase1b, Phase2a] FDS score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  6. [Phase1b, Phase2a] ONLS score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  7. [Phase1b, Phase2a] 10MWT score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  8. [Phase 1b] Change in grade of fatty infiltration in the proximal lower extremities (According to Goutallier classification scale)

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 24 weeks compared to baseline (Visit 2)

  9. [Phase1b, Phase2a] Change in Motor Nerve Conduction Velocity (Unit: m/s)

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  10. [Phase1b, Phase2a] Change in Compound Muscle Action Potential (Unit: ㎷)

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  11. [Phase1b, Phase2a] Change in Sensory Nerve Action Potential (Unit: ㎶)

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  12. [Phase1b, Phase2a] Change in Sensory Nerve Conduction Velocity (Unit: m/s)

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 4, 8, 18, and 24 weeks compared to baseline (Visit 2)

  13. SF-36v2 score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 24 weeks compared to baseline (Visit 2)

  14. [Phase1b, Phase2a] Adverse Event

    By cohort that Number of subjects, incidence rate (%), confidence interval (two-sided 95%), presents the number of occurrences. Additional, The pre-treatment adverse event that occurred before administration of clinical trial drugs is presented in detail.

    Time frame: Up to 24weeks. However, adverse drug reactions that persist at the end of the clinical trial will be followed up until the possible adverse reactions are resolved or it is determined that further follow-up is not meaningful.

  15. [Phase1b, Phase2a] Vital sign

    Number of participants with clinically significant abnomalities in vital signs after EN001 administration. Vital Signs include blood pressure (mmHg), pulse (times/minute), respiratory rate (times/minute), and body temperature (℃) and will be assessed. By cohort and visit, present continuous variables with subject count, mean, standard deviation, median, minimum, and maximum. For categorical variables, provide shift table.

    Time frame: Up to 24 weeks

  16. [Phase1b, Phase2a] Laboratory examination

    Number of participants with clinically significant abnormalities in Laboratory parameters after EN001 administration. Hematological tests, Blood chemical tests, Blood coagulation test, Urine test, Serum virus test. It is conducted through blood and urine collection, and the PI checks whether the test results are normal, abnormal, and clinically significant.

    Time frame: Up to 24 week. Serum virus testing is performed only during screening. At Baseline and Week 4, hematological tests, blood chemical tests, TCO2, Mg, and blood coagulation tests are performed before and within 4 hours after administration of the IP.

  17. [Phase1b, Phase2a] electrocardiography

    Number of participants with clinically significant abnormalities in electrocardiography after EN001 administration. Based on the PR Interval, QRS Duration, QTc Interval and QTcF Interval, PI checks whether the test results are normal, abnormal, and clinically significant. by cohort and visit, present continuous variables with subject count, mean, standard deviation, median, minimum, and maximum. For categorical variables, provide shift table.

    Time frame: At Baseline, Week 4, Week 8, Week 12, Week 18, Week 24

  18. [Phase1b, Phase2a] X-ray

    by cohort and visit, present continuous variables with subject count, mean, standard deviation, median, minimum, and maximum. For categorical variables, provide shift table.

    Time frame: Before administration of investigational product at Baseline and Week 4 and within 4 hours after completion of administration

  19. [Phase1b, Phase2a] Physical Examinations

    Number of participants with clinically significant abnormalities in Physical Examinations after EN001 administration. Based on general appearance, head, ears/eyes/nose/throat, cardiovascular, respiratory, abdomen, skin, lymph nodes, extremities, musculoskeletal and neurologic, PI checks whether the test results are normal, abnormal, and clinically significant. By cohort and visit, present continuous variables with subject count, mean, standard deviation, median, minimum, and maximum. For categorical variables, provide shift table.

    Time frame: Up to 24 weeks

07

Study locations

3 of 3 sites recruiting
  • Dongguk University Gyeongju Hospital
    Gyeongju, South Korea
    Recruiting
    • Jin-Mo Park · Principal investigator
  • Kyung Hee University Hospital at Gangdong
    Seoul, South Korea
    Recruiting
    • Sang Beom Kim · Principal investigator
  • Samsung Medical Center
    Seoul, South Korea
    Recruiting
    • Byung-Ok Choi · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Mar 25, 2024
StartActual
May 30, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06328712
Lead sponsor
ENCell
Responsible party
Sponsor
First posted
Mar 25, 2024
Start date
May 30, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 26, 2026

Study contacts

ENCell
Contact
encell@encellinc.com
+82-2-6205-8054

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EN001

Start the discussion